Navigation Links
Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results
Date:3/7/2013

its website as one means of disclosing material non-public information, and investors are encouraged to monitor Cadence's website in addition to following the company's press releases, SEC filings and public conference calls and webcasts.

About OFIRMEV® (Acetaminophen) InjectionOFIRMEV (acetaminophen) injection (1000 mg / 100 mL, 10 mg / mL; for intravenous use only), Cadence Pharmaceuticals' proprietary intravenous formulation of acetaminophen, is indicated for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever. The FDA approval of OFIRMEV was based on data from clinical trials in approximately 1,020 adult and 355 pediatric patients. These trials included two studies evaluating the safety and effectiveness of OFIRMEV in the treatment of pain, and one study evaluating OFIRMEV in the treatment of fever. The effectiveness of OFIRMEV for the treatment of acute pain and fever has not been studied in pediatric patients less than 2 years of age.

Important Safety InformationDo not exceed the maximum recommended daily dose of acetaminophen. Administration of acetaminophen by any route in doses higher than recommended may result in hepatic injury, including the risk of severe hepatotoxicity and death. OFIRMEV is contraindicated in patients with severe hepatic impairment, severe active liver disease or with known hypersensitivity to acetaminophen or to any of the excipients in the formulation. Acetaminophen should be used with caution in patients with the following conditions: hepatic impairment or active hepatic disease, alcoholism, chronic malnutrition, severe hypovolemia, or severe renal impairment. OFIRMEV should be administered only as a 15-minute intravenous infusion. Discontinue OFIRMEV immediately if symptoms associated with allergy or hypersensitivity occur. Do not use in patients with acetaminophen allergy. The most common adverse reactio
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Fourth Quarter And Full Year 2012 Financial Results On March 7, 2013
2. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Cowen & Company 33rd Annual Health Care Conference In Boston On March 5, 2013
3. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Leerink Swann Global Healthcare Conference In New York City On February 13, 2013
4. Cadence Pharmaceuticals Estimates Fourth Quarter 2012 Net Product Revenue and Provides Full Year 2013 Revenue Guidance
5. Cadence Pharmaceuticals Announces Termination of Option Agreement to Acquire Incline Therapeutics, Inc.
6. Cadence Pharmaceuticals to Host Analyst and Investor Day
7. Cadence to Open Finished Medical Device Facility
8. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Piper Jaffray 24th Annual Healthcare Conference In New York City On November 28, 2012
9. Cadence Pharmaceuticals Reports Third Quarter 2012 Financial Results
10. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Third Quarter 2012 Financial Results On November 5, 2012
11. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Stifel Nicolaus Healthcare Conference 2012 In Boston On September 5, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly larger ... painless for patients to self-inject prescription drugs in the large ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to $220B by 2018, according to analysts.   Many of these ...
(Date:1/14/2014)... , Jan. 14, 2014 The Brandeis Medical Center, led by ... a premier and affordable laser tattoo removal experience with the ... focus is in providing high quality cosmetic services with cutting edge ... " Southern California has seen a dramatic ...
(Date:1/14/2014)... PLYMOUTH, Minn. , Jan. 14, 2014   NuAire , a ... come to agreement with Hitachi Koki of ... centrifuges in North America . NuAire will utilize ... and Canada to offer assistance ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2NuAire announces sales and service of Hitachi Koki centrifuges in North America 2
... 2011 The American Association for Homecare strongly endorses ... Medicare "competitive" bidding program for home medical equipment and ... introduced by Congressmen Glenn Thompson (R-Pa.) and Jason Altmire ... "Fairness in Medicare Bidding Act."   ...
... 2011 AstraZeneca today announced enrolment of the first ... an oral peripherally-acting opioid antagonist being investigated for the ... programme is designed to investigate the safety and efficacy ... constipation, a common side effect of prescription opioids when ...
Cached Medicine Technology:Home Medical Equipment Group Supports Bipartisan Bill to Repeal the Controversial Medicare 'Competitive' Bidding Program for Homecare 2Home Medical Equipment Group Supports Bipartisan Bill to Repeal the Controversial Medicare 'Competitive' Bidding Program for Homecare 3AstraZeneca Initiates Phase III Clinical Programme Evaluating NKTR-118 for Treatment of Opioid-Induced Constipation 2AstraZeneca Initiates Phase III Clinical Programme Evaluating NKTR-118 for Treatment of Opioid-Induced Constipation 3
(Date:4/24/2014)... professor in the new Institute for Biomedical Sciences ... $2.83 million federal grant to develop novel therapeutics ... grant from the Eunice Kennedy Shriver National Institute ... National Institutes of Health will support Plemper,s drug ... at least one distinct alternative compound. , Infections ...
(Date:4/24/2014)... epidemic of prescription opioid overdose deaths was outlined yesterday ... by leaders of agencies in the U.S. Department of ... health care providers to expand their use of medications ... describes a number of misperceptions that have limited access ... how medications can be used in combination with behavior ...
(Date:4/24/2014)... was the first in the world to discover a ... the jaw. , Ameloblastoma is an odontogenic tumour with ... most often found in the posterior of the lower ... tissue deficiencies in the jaws as well as loss ... the need for surgery and the recurrence of ameloblastoma, ...
(Date:4/24/2014)... Foundation has awarded LSU Health Sciences Center New ... grant in the amount of $295,635. The funding ... social and educational backgrounds, underrepresented in the sciences, ... project will provide students with training for 10 ... will be led by Principal Investigator Dr. Fern ...
(Date:4/23/2014)... General Hospital (MGH) investigators may lead to greater availability ... medical problem use of fecal material from healthy ... Clostridium difficile ( C. difficile ) bacteria. ... Clinical Infectious Diseases , the researchers report that ... to patients was as successful in curing recurrent ...
Breaking Medicine News(10 mins):Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 3Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 4Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 2Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 3
... This release is available in German . ... and learning about the warning signs of lymphedema: that,s ... lymphedema, according to the German Institute for Quality and ... about how to protect themselves from this common and ...
... AUGUSTA, Maine, Nov. 6 Building on the ... for small businesses in Maine,the Maine State Chamber ... and Blue Shield have announced further additions to ... January, Chamber,BlueOptions will include eight health plans from ...
... Invisicare Is Put In Place, LAS VEGAS, ... the developers of Invisicare, a patented polymer,delivery system ... of Geert Cauwenbergh, PhD to head its International,Advisory ... expand the demand,for Invisicare in international markets. Dr. ...
... Nov. 6 /Xinhua-PRNewswire-FirstCall/ -- Tianyin,Pharmaceutical, Co., Inc., (Amex: ... traditional Chinese medicine ("TCM") based in Chengdu, China,today ... to discuss its,2009 fiscal first quarter at 8:30 ... will be released that day before the market ...
... A steady march toward using,ever-more "patient-friendly" ... proceedings of the 37th Global Congress of ... international professional society for,specialists in minimally invasive ... preserving the highest possible quality of,life for ...
... People With,Diabetes and Their Caregivers, WESTPORT, Conn., Nov. ... laughter, and family, usually accompanied by trays of cookies,cakes, ... some,of the nearly 24 million people in America with ... dLife helped over 100,000 online,visitors survive the season with ...
Cached Medicine News:Health News:How women can improve their quality of life after breast cancer treatment 2Health News:Chamber BlueOptions Insurance Adds to its Options and Benefits for 2009 Suite of Insurance Plans Meeting Small Business Needs 2Health News:Chamber BlueOptions Insurance Adds to its Options and Benefits for 2009 Suite of Insurance Plans Meeting Small Business Needs 3Health News:Skinvisible Appoints Dr. Geert Cauwenbergh to Its International Advisory Board 2Health News:Skinvisible Appoints Dr. Geert Cauwenbergh to Its International Advisory Board 3Health News:Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 First Quarter Earnings Conference Call on Tuesday, November 11, 2008 at 8:30 a.m. EST 2Health News:Hi-Tech Advances the Practice of Minimally Invasive Gynecology at AAGL Global Congress 2Health News:Hi-Tech Advances the Practice of Minimally Invasive Gynecology at AAGL Global Congress 3Health News:Hi-Tech Advances the Practice of Minimally Invasive Gynecology at AAGL Global Congress 4Health News:Back By Popular Demand - dLife Holiday Helpline 2
... System 9700 can now be used with ... The aluminum block has been designed for ... sequencing in a conventional 8 X 12 ... system to be used in 9600 emulation ...
96 well thermocycler with unique High Temperature Range (HTR) Peltier technology for fastest available heating and cooling rates up to 4C/sec with High Pressure Lid for automated sealing of PCR plate...
... for day-to-day temperature cycling ... 0.1C ,30% reduction in ... or coolant-based cyclers ,4 ... ramping ,Options for oil-free ...
... TC-512 has a graphical touch screen display ... at the "touch of a screen." ... gradient, Touch Screen, Graphical Display, Memory Cards, ... Block Format, Intuitive Programmin, Free Instrument Software ...
Medicine Products: